Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sanofi is conducting a Phase 2 study titled ‘A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate-to-severe Ulcerative Colitis.’ The study aims to assess the efficacy of different doses of SAR441566 in achieving clinical remission in patients with moderate-to-severe ulcerative colitis.
The intervention being tested is SAR441566, an oral drug administered in tablet form. The study includes three experimental dose regimens of SAR441566 and a placebo group to evaluate the drug’s effectiveness and safety.
The study design is interventional with a randomized allocation and a parallel intervention model. It employs quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are blinded. The primary purpose is treatment.
The study began on March 28, 2025, and the last update was submitted on June 30, 2025. These dates mark the study’s progression and ensure transparency in the research process.
This clinical study could influence Sanofi’s stock performance positively if the results show significant efficacy and safety, enhancing investor confidence. It also positions Sanofi competitively within the pharmaceutical industry, particularly in the treatment of ulcerative colitis.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.